Top Tweets for #CheckMate227
Post hoc results from #CheckMate227 part 1 showed that intracranial efficacy outcomes favored nivolumab plus ipilimumab versus chemotherapy in those with or without brain metastases.
Study in @JTOonline by @MartinReck2, @JulieBrahmer and colleagues ➡️ https://t.co/C6PGR6sdlP
#ASCO22 | Francesco Grossi about the amazing results of #CheckMate227 and #CheckMate9LA trials:
"From both studies we have confirmation of long survival with NIVO + IPI alone or in combination with chemotherapy." #NSCLC
🚨🔊💥@OncoAlert informative update of #Checkmate227 with 4y OS. Nivo+ipi continues to provide consist OS benefit in both ITT ( PD-L1+) but also in PD-L1 NEG group. Since no #EMA approval,IMO CM-9A covers this gap with short chemo to abolish deaths in 1st 6m @myESMO #lcsm #some
Four year follow up on CheckMate 227 now @JTOonline. OS favors 1L nivolumab + ipilimumab vs chemo for PDL1+ NSCLC (HR 0.76, 4y OS rate 29% vs 18%) and PDL1- (HR 0.64, 4y rate 24% vs 10%). Those who stop nivo/ipi for toxicity retain long term OS benefit.
https://t.co/jOsSPlDxDi
ヤーボイについての動画
⇒ https://t.co/HpAn0ua1L2 #アメブロ @ameba_officialより
新たな作用機序の免疫チェックポイント阻害薬であるヤーボイについてYouTube動画を作成しました。
#ヤーボイ
#イピリムマブ
#CheckMate227
#ASCO20 | Come armonizzare il trattamento in prima linea tra combinazione #nivolumab+#ipilimumab e chemioterapia nel #NSCLC? A questa domanda contribuiscono senza dubbio a rispondere i due trial #CheckMate227 Part 1 e #CheckMate9LA presentati all'@ASCO.
https://t.co/AbT8Z6Shs4
Don't miss our webinar today at 1:30pm with Winship's @RamalingamMD and @SagarLonialMD discussing #CheckMate227 and #DREAMM2 respectively, and providing an overview of Winship research featured at #ASCO20. Register for free at https://t.co/xs599kPG2a.
Our Vice Chair, @tnewsomdavis has written two blogs on studies presented at #ESMO19. Take a look at his summaries of the #FLAURA and #Checkmate227 studies. https://t.co/K51S9m5CBa
【非小細胞肺癌のNivo+IPI OS改善】
#m3
#CheckMate227
未治療ステージIV NSCLCを対象に、ニボルマブとイピリムマブ併用の効果をみた第III相試験
→PD-L1 1％以上でのOS中央値は
併用療法群17.1カ月
化学療法群14.9カ月（P＝0.007）
https://t.co/G1cImR3pqd
Ipi+ nivo improved OS in aNSCLC, regardless of PD-L1 (#Checkmate227), but the bar is still <2 years: what is more insightful?
Checkmate 227 Ipi+Nivo: OS improved, regardless of PD-L1, but is still <2 years @peters_solange #ESMO19 #lcsm #checkmate227
@marinagarassino @giorgioscaglio3 @StephenRameyMD @CarloGenova5 @g_mountzios @RobertoFerrara_ @RamalingamMD
小野&ブリストル社からのプレスリリース。checkmate-227試験のパート1aでニボルマブ＋低用量イピリムマブの有効性が示される。非小細胞肺癌でもIO-IO併用の時代が到来しそうですね😄
#ニボルマブ
#イピリムマブ
#checkmate227 https://t.co/rTHO3vdVrF
Interesting to know if in the big trials #Checkmate227 #Mystic we can see from subgroup analyses the clinical effect in patients who received radiotherapy. If this is true there can be a new era for #antiCTLA4 in #NSCLC #LCAM
great article, very interesting data: a must-read on RT/IO combination for NSCLC by our colleagues from @WeillCornel https://t.co/pBOROfQqMx @_ShankarSiva @marinagarassino @DrewMoghanaki @CVanpouilleBox @rweichselbaum @ACKoongMDPhD @gerryhanna @fifimcdrmh @NP_Rudqvist
Tumor mutational burden is an important and independent biomarker in advanced NSCLC per #CheckMate227 https://t.co/Uzr2twTHez
in another @NEJM publication & @AACR presentation, ipilimumab + nivo ⬆️ PFS vs chemo in 1st line metastatic NSCLC with high tumour mutational burden (TMB) (>10 mutations per megabase) assessed by CDx assay https://t.co/7NnW1uPmrp #lcsm #immunotherapy #checkmate227
News: Better #PFS with #nivolumab + #ipilimumab than with #chemotherapy in patients with advanced #NSCLC who have a high tumor mutational burden, Matthew Hellman (from @sloan_kettering) et al report at #AACR18. @NEJM #CheckMate227 https://t.co/R84INPrbE2
This phase III study shows superior progression-free survival with first-line combination immunotherapy in a predefined population of NSCLC patients with high tumor mutation burden @ASCOPost https://t.co/xBERr2Y3bR #CheckMate227 #lungcancer
Last Seen Hashtags on Sotwe
HensNight
Seen from United Kingdom
ARDAWorld
Seen from United States
BabaSaliNights
Seen from Turkey
steelbdsm
Seen from France
minichat video,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Seen from United States
balaibandung
Seen from United States
松本乱菊
Seen from Japan
asian femboy+fuck
Seen from Korea
lesbianskisses
Otew2019
Seen from United States
Most Popular Users
Elon Musk 
@elonmusk
241.7M followers
Barack Obama
@barackobama
119M followers
Cristiano Ronaldo
@cristiano
114.5M followers
Donald J. Trump
@realdonaldtrump
111.9M followers
Narendra Modi
@narendramodi
107.2M followers
Rihanna
@rihanna
98.7M followers
NASA
@nasa
92.4M followers
Justin Bieber
@justinbieber
91.8M followers
KATY PERRY
@katyperry
90M followers
Taylor Swift
@taylorswift13
84M followers
Lady Gaga
@ladygaga
75.4M followers
Virat Kohli
@imvkohli
73.4M followers
Kim Kardashian
@kimkardashian
70.9M followers
YouTube
@youtube
68.8M followers
Neymar Jr
@neymarjr
66.4M followers
Bill Gates
@billgates
65.2M followers
Selena Gomez
@selenagomez
63.1M followers
The Ellen Show
@theellenshow
62.3M followers
CNN
@cnn
61.8M followers
X
@x
60.7M followers